A Rare Cause of Retroperitoneal Fibrosis in Adults: H Syndrome Presenting After 35 Years- A Case Report
DOI:
https://doi.org/10.61882/npz6gc25Keywords:
Retroperitoneal fibrosis, H syndrome, SLC29A3gene mutation, Adult onset H syndrome, Renal failureAbstract
Introduction. Retroperitoneal fibrosis (RPF) is a rare fibro- inflammatory disorder that may cause urinary tract obstruction and renal failure. Although most RPF cases are IgG4-related, rare genetic conditions can also contribute to the disease. H syndrome, an autosomal recessive disorder caused by biallelic SLC29A3 mutations, usually presents in childhood with cutaneous, endocrine, and systemic manifestations; adult onset is exceptionally rare. Case presentation. A 36-year-old woman was admitted to hospital with the complaint of nausea, vomiting, and oliguria. Laboratory tests showed urea 116 mg/dL, creatinine 5,8 mg/dL,. Non-contrast computed tomography imaging revealed bilateral hydronephrosis and a 2,5 cm retroperitoneal fibrotic mass encasing the abdominal aorta and iliac arteries. Extensive evaluation—including positron emission tomography, lymph-node histology, and autoimmune/ IgG4 serology—found no evidence of malignancy, infection, or IgG4- related disease. Family history disclosed parental consanguinity and a brother with H syndrome. Next-generation sequencingidentified a homozygous SLC29A3 (NM_018344.5):c.1339G > A (p.Glu447Lys) mutation, confirming H syndrome. Bilateral ureteral stenting and corticosteroid therapy led to full renal recovery
(creatinine 0.7 mg/dL).
Conclusion. This case expands the clinical spectrum of H syndrome by documenting late-onset RPF without typical dermatologic or auditory signs. Recognition of familial risk and timely genetic testing were decisive for diagnosis. Early decompression and immunosuppression preserved renal function. Reporting suchatypical presentations increases awareness of H syndrome as a rare genetic cause of RPF and supports comprehensive genetic evaluation in adults with unexplained retroperitoneal fibrosis.
Downloads
References
1. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep. 2021 Feb 10;23(3):18.
2. Duhan S, Keisham B, Bazigh K, Duhan C, Alhamdan N. Retroperitoneal Fibrosis: Still a Diagnostic Challenge. Cureus. 2023 Jan 20;15(1):e33998.
3. Honsali R, Tahiri L, Cherkaoui-Dekkaki S, Allali F. Rheumatological manifestations of H syndrome. Reumatologia. 2024;62(4):294-303.
4. Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, Lowichik A, Bohnsack JF. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J. 2017 Oct 17;15(1):76.
5. Hamad A, Elwaheidi H, Salameh F, Alyahya M, El Fakih R, Aljurf M. H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature. Hematol Oncol Stem Cell Ther. 2024 Jul-Sep 01;17(3):159-167.
6. Al-Haddab M, Al Muqarrab FJ, Alhumidi A, Alkofide M. Clinical Progression and Manifestations of H Syndrome: A Case Report of Failed Treatment Option. Am J Case Rep. 2024 Jun 8;25:e944198.
7. Jacquot R, Jouret M, Valentin MG, Richard M, Jamilloux Y, Rousset F, Emile JF, Haroche J, Steinmüller L, Zekre F, Phan A, Belot A, Seve P. H syndrome treated with Tocilizumab: two case reports and literature review. Front Immunol. 2023 Aug 11;14:1061182.
8. Jeremiah N, Awad F, Sticht H, et al. Functional and structural insights into the SLC29A3 transporter: Identifying the molecular basis of H syndrome. J Invest Dermatol. 2014;134(2):557-561.
9. Vural S, Ertop P, Durmaz CD, et al. Skin-Dominant Phenotype in a Patient with H Syndrome: Identification of a Novel Mutation in the SLC29A3 Gene. Cytogenet Genome Res. 2017;151(4):186-190.
10. Fikri C, Aboudouraib M, Sab IA, Amal S, Hocar O. H Syndrome: Three New Cases from Morocco. Skinmed. 2024 Aug 2;22(3):225-227.
11. Tesser A, Valencic E, Boz V, Tornese G, Pastore S, Zanatta M, Tommasini A. Rheumatological complaints in H syndrome: from inflammatory profiling to target treatment in a case study. Pediatr Rheumatol Online J. 2024 Jan 23;22(1):21